Public Health and Overdose Policy

Researchers from the University of Houston and biotech firm ARMR Sciences are advancing a first-of-its-kind fentanyl vaccine into a phase 1 clinical trial in early 2026 at the Center for Human Drug Research in the Netherlands after promising mouse and rat studies. The vaccine uses a synthetic fentanyl fragment linked to protein CRM197 and an immune stimulant (dmLT) to induce antibodies that bind fentanyl in the bloodstream, preventing it from crossing the blood–brain barrier, producing euphoria or causing respiratory depression and overdose. If proven safe and effective in humans, it would be the first preventive therapy aimed specifically at blocking fentanyl’s effects, complementing but differing from reversal drugs like naloxone.